Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985 Apr;54(1):53-7.
doi: 10.1128/JVI.54.1.53-57.1985.

Cytotoxic T-lymphocyte reactivity with individual Sendai virus glycoproteins

Cytotoxic T-lymphocyte reactivity with individual Sendai virus glycoproteins

M N Al-Ahdal et al. J Virol. 1985 Apr.

Abstract

Liposomes were constituted with affinity-purified Sendai virus glycoproteins HN and F and phosphatidylcholine (PC) or phosphatidylethanolamine: phosphatidylserine (PEPS). The glycoprotein-bearing recombinant vesicles (RV) were used to modify the surface of P815 mastocytoma cells (H-2d) or EL4 lymphoma cells (H-2b). The cells treated with HN-F-PCRV, HN-PEPSRV, or F-PEPSRV were shown by surface immunofluorescence to retain antigen for at least 2 h at 37 degrees C after treatment. The modified cells were used in cytotoxicity assays with effector spleen cells from either DBA/2 (H-2d) or C57BL/6 (H-2b) immunized by inoculation of active Sendai virus. Cells modified by treatment with HN/F-PCRV showed susceptibility to cytolysis similar to that in actively infected cells. Cells modified with HN-PEPSRV or with F-PEPSRV were also susceptible. The sum of reactivities of the anti-HN component and the anti-F components was close to that seen with HN- and F-bearing targets. Syngeneic but not allogeneic target cells expressing Sendai virus glycoproteins were bound and lysed by the effector cells, which was expected if the interactions were major histocompatibility complex restricted. The activity was attributed to cytotoxic T lymphocytes, since it was depleted by treatment with anti-Thy 1.2 antibody and complement.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Mol Biol. 1974 Mar 15;83(4):427-36 - PubMed
    1. Nature. 1977 May 12;267(5607):160-3 - PubMed
    1. Anal Biochem. 1976 May 7;72:248-54 - PubMed
    1. Immunology. 1976 Jul;31(1):27-32 - PubMed
    1. Nature. 1977 Nov 17;270(5634):251-3 - PubMed

Publication types

MeSH terms